18 January 2024 - Eisai announced today that it has obtained marketing authorisation approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in house discovered anti-epileptic drug Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.

Fycompa is a first in class anti-epileptic drug discovered at Eisai’s Tsukuba Research Laboratories.

Read Eisai press release